2-morpholin-4-yl-1-(4-nitro-phenyl)-ethanone | 79378-15-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-morpholin-4-yl-1-(4-nitro-phenyl)-ethanone
• 英文别名: 4-Nitro-α-morpholino-acetophenon；2-Morpholin-4-yl-1-(4-nitrophenyl)ethanone
• CAS: 79378-15-7
• 化学式: C₁₂H₁₄N₂O₄
• mdl: MFCD02028729
• 分子量: 250.254
• InChiKey: RIDJIJUABGPIDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  75.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-morpholin-4-yl-1-(4-nitro-phenyl)-ethanone 在 palladium 10% on activated carbon 氢气 作用下， 以 乙酸乙酯 为溶剂， 反应 1.0h， 生成 1-(4-Aminophenyl)-2-morpholinylethanone
  参考文献：
  名称：

  WO2006/118749

  摘要：

  公开号：
• 作为产物：
  描述：

  吗啉 、 2-溴-4'-硝基苯乙酮 以affords the novel intermediate 1-(4-nitrophenyl)-2-morpholinylethanone which when的产率得到2-morpholin-4-yl-1-(4-nitro-phenyl)-ethanone
  参考文献：
  名称：

  Method of protecting human skin from ultraviolet radiation

  摘要：

  4-硝基苯乙酰溴与吗啡啉反应得到新型中间体1-(4-硝基苯基)-2-吗啡啉基乙酮，还原后得到新型防晒剂1-(4-氨基苯基)-2-吗啡啉基乙酮。

  公开号：

  US04282206A1

文献信息

• Lewis acid catalyzed rapid synthesis of 5-hydroxy-benzo[g]indole scaffolds by a modified Nenitzescu reaction
  作者：Moyurima Borthakur、Shyamalee Gogoi、Junali Gogoi、Romesh C. Boruah

  DOI：10.1016/j.tetlet.2010.07.129

  日期：2010.9

  A fast solvent-less synthesis of 5-hydroxy-benzo[g]indole scaffolds is accomplished from Lewis acid-catalyzed one-pot reaction of naphthoquinone, ω-morpholinoacetophenone, and urea under microwave irradiation. The key step in the synthesis is the Michael addition followed by in situ aza cyclization reaction using urea as an environmentally benign source of ammonia.

  5-羟基-苯并[ g ]吲哚支架的快速无溶剂合成是通过微波辐射下路易斯酸催化的萘醌，ω-吗啉代乙酰苯和尿素的一锅反应完成的。合成中的关键步骤是迈克尔加成反应，然后使用尿素作为环境友好的氨源进行原位氮杂环化反应。
• Chemical compounds
  申请人：Ratcliffe James Andrew

  公开号：US20050009831A1

  公开（公告）日：2005-01-13

  The present invention concerns compounds of general formula (I): in which: R 1 represents hydrogen, R 4 , —C(═Y)—NHR 4 , —SO 2 NHR 4 , —C(=Z 1 )—R 4 , —SO 2 —R 4 or —C(=Z 1 )—OR 4 ; R 2 represents hydrogen, cyano, halogen or —C≡C—R 5 ; R 3 represents hydrogen, acyl, alkoxycarbonyl, alkyl, aroyl, aryl, aryloxycarbonyl, carboxy, cycloalkenyl, cycloalkyl, heteroaroyl, heteroaryl, heterocycloalkyl or —C(═O)—NY 1 Y 2 ; R 4 represents optionally substituted alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl or heteroaryl R 5 represents hydrogen or alkyl; R 6 represents alkyl, acyl, alkoxycarbonyl, alkylsulfonyl, aryl, arylsulfonyl, aroyl, cycloalkyl, cycloalkenyl, heteroaryl, heteroarylsulfonyl, heteroaroyl and heterocycloalkyl; R 7 represents optionally substituted alkyl, cycloalkyl or cycloalkylalkyl, R 8 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; R 9 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R 10 represents hydrogen or lower alkyl; R 11 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; or alkyl optionally substituted by —NY 1 Y 2 ; R 12 represents aryl or heteroaryl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted Y represents O, S or NCN; Y 1 and Y 2 (Y 3 and Y 4 ) are independently in particular hydrogen, alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocycloalkyl; or the group —NY 1 Y 2 may form 5-7 membered ring or the group —NY 3 Y 4 (—NY 5 Y 6 ) may form a cyclic amine; Z (Z 1 ) represents O or S; Z 2 represents O or S(O) p ; n is zero or an integer 1 or 2; m is 1 or 2; p is 1 or 2; and their corresponding N-oxides, their prodrugs; their pharmaceutically acceptable salts and solvates (e.g. hydrates), also together with one or more pharmaceutically acceptable carriers or excipients, such novel indolizines derivatives with inhibitory effects towards kinase proteins and especially for use for preventing or treating diseases that may be modulated by the inhibition of such kinase proteins and particularly solid tumours.

  本发明涉及通式（I）的化合物： 其中： R1代表氢，R4，—C（═Y）—NHR4，—SO2NHR4，—C（=Z1）—R4，—SO2—R4或—C（=Z1）—OR4； R2代表氢，氰基，卤素或—C≡C—R5； R3代表氢，酰基，烷氧羰基，烷基，芳酰基，芳基，芳氧羰基，羧基，环烯基，环烷基，杂芳酰基，杂芳基，杂环烷基或—C（═O）—NY1Y2； R4代表可选取代的烷基，环烷基，环烯基，杂环烷基，芳基或杂芳基； R5代表氢或烷基； R6代表烷基，酰基，烷氧羰基，烷基磺酰基，芳基，芳基磺酰基，芳酰基，环烷基，环烯基，杂芳基，杂芳基磺酰基，杂芳酰基和杂环烷基； R7代表可选取代的烷基，环烷基或环烷基烷基； R8代表氢，烷基，烯基，芳基，芳基烷基，杂芳基或杂芳基烷基； R9代表烷基，芳基，芳基烷基，环烷基，环烷基烷基，杂芳基，杂芳基烷基，杂环烷基或杂环烷基烷基； R10代表氢或较低的烷基； R11代表烷基，芳基，芳基烷基，环烷基，环烷基烷基，杂芳基，杂芳基烷基，杂环烷基或杂环烷基烷基；或可选取代的烷基，被—NY1Y2取代； R12代表芳基或杂芳基；或可选取代的烷基，环烷基，环烷基烷基，杂环烷基或杂环烷基烷基； Y代表O，S或NCN； Y1和Y2（Y3和Y4）特别是独立的氢，烷基，芳基，环烷基，环烯基，杂芳基或杂环烷基；或该基团—NY1Y2可能形成5-7成员环或该基团—NY3Y4（—NY5Y6）可能形成一个环状胺； Z（Z1）代表O或S； Z2代表O或S（O）p； n为零或整数1或2； m为1或2； p为1或2； 以及它们对应的N-氧化物，它们的前药；它们的药物可接受的盐和溶剂化合物（例如水合物），还包括一个或多个药物可接受的载体或赋形剂，这种新的吲哚嗪衍生物具有对激酶蛋白的抑制作用，特别是用于预防或治疗可能通过抑制这种激酶蛋白而调节的疾病，特别是固体肿瘤。
• Method of protecting human skin from ultraviolet radiation
  申请人：Westwood Pharmaceuticals Inc.

  公开号：US04282206A1

  公开（公告）日：1981-08-04

  Reaction of 4-nitrophenacyl bromide with morpholine affords the novel intermediate 1-(4-nitrophenyl)-2-morpholinylethanone which when reduced yields the novel sunscreen 1-(4-aminophenyl)-2-morpholinylethanone.

  4-硝基苯乙酰溴与吗啡啉反应得到新型中间体1-(4-硝基苯基)-2-吗啡啉基乙酮，还原后得到新型防晒剂1-(4-氨基苯基)-2-吗啡啉基乙酮。
• JNK INHIBITORS
  申请人：Nemecek Conception

  公开号：US20070238734A1

  公开（公告）日：2007-10-11

  The present invention concerns compounds of general formula (I): in which the substituents are as described herein.

  本发明涉及一般式（I）的化合物： 其中取代基如本文所述。
• Thia-tetraazaacenaphthylene kinase inhibitors
  申请人：Battista A. Kathleen

  公开号：US20070265264A1

  公开（公告）日：2007-11-15

  The present invention is directed to novel thia-tetraazaacenaphthylene compounds of Formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of ATP-protein kinase interactions.

  本发明涉及公式(I)的新型硫代四氮杂蒽化合物及其药学上可接受的形式，以及它们的合成和用作ATP-蛋白激酶相互作用抑制剂的用途。